EFFECTS OF MEDICAL THERAPY, ALCOHOL, SMOKING, AND ENDOCRINE DISRUPTORS ON MALE INFERTILITY

Fábio Firmbach Pasqualotto, Antônio Marmo Lucon, Bernardo Passos Sobreiro, Eleonora Bedin Pasqualotto and Sami Arap

Infertility affects up to 15% of the sexually active population, and in 50% of cases, a male factor is involved, either as a primary problem or in combination with a problem in the female partner. Because many commonly encountered drugs and medications can have a detrimental effect on male fertility, the medical evaluation should include a discussion regarding the use of recreational and illicit drugs, medications, and other substances that may impair fertility. With the knowledge of which drugs and medications may be detrimental to fertility, it may be possible to modify medication regimens or convince a patient to modify habits to decrease adverse effects on fertility and improve the chances of achieving a successful pregnancy.

Concern is growing that male sexual development and reproduction have changed for the worse over the past 30 to 50 years. Although some reports find no changes, others suggest that sperm counts appear to be decreasing and that the incidence of developmental abnormalities such as hypospadias and cryptorchidism appears to be increasing, as is the incidence of testicular cancer. These concerns center around the possibility that our environment is contaminated with chemicals – both natural and synthetic – that can interact with the endocrine system.

fertility.footnote-5footnote-6 Equipped with the knowledge of which drugs and medications may be detrimental to fertility, it may be possible to modify medication regimens or convince a patient to modify habits to decrease adverse effects on fertility and improve the chances of achieving a successful pregnancy.

Basically, there are 4 mechanisms by which drugs and medications impair male fertility: by exerting a gonadotoxic effect on the testicles, by altering the hypothalamic-pituitary-gonadal (HPG) axis, by impairing ejaculation and erectile function, and by decreasing libido.footnote-10

Gonadotoxins directly affect testicular sperm production, resulting in suboptimal sperm density, maturation, motility, or morphology.footnote-10footnote-13 Several substances alter the delicately balanced HPG axis, causing either a decline in pituitary-secreted gonadotropins or an alteration in intratesticular testosterone concentrations.footnote-2 Ejaculation may be impaired by drugs that cause retrograde ejaculation, block spinal reflexes, or inhibit emission, resulting in a dry ejaculation. Erectile dysfunction may occur with drugs that interfere with either neurologic or vascular mediated events necessary for normal erection to occur. Finally, several medications interfere with normal male libido through their actions on the central nervous system (CNS).footnote-1footnote-5footnote-6

Recreational and illicit drugs

Agents in this category that can affect male fertility include alcohol, tobacco, and illicit drugs.

Alcohol

Long-term effects of chronic alcohol use include erectile dysfunction, reduced libido, and gynecomastia.footnote-14 One mechanism of these effects is a reduction in serum testosterone caused by decreased testicular production and increased metabolic clearance in the liver. It is thought that alcoholism and hepatic cirrhosis cause alterations in the HPG axis, resulting in testicular dysfunction.footnote-14 In addition, the oxidation of alcohol competes with testicular production of testosterone. These mechanisms lead to subsequent decrease in semen volume and sperm density. Another factor appears to be an elevation in serum estrogen caused by peripheral conversion of testosterone to estrogen through increased activity of the enzyme aromatase, which is present both in the liver and in peripheral fat cells.footnote-19

“Social” or light alcohol ingestion does not appear to interfere with semen quality.footnote-6 However, excessive acute alcohol intake does have adverse effects on male fertility by causing decreased serum testosterone concentrations. Impairment of spinal reflexes, also caused by excessive alcohol abuse, leads to reduced sensation and innervation of the penis, and thus may also contribute to erectile dysfunction.footnote-14

Cigarette smoking

Many studies have examined the effects of cigarette smoking on fertility, and cumulative evidence suggests that smoking has a significant negative impact on sperm production, motility, and morphology.footnote-6 Several reports demonstrated that the mutagenic and carcinogenic components of cigarette smoke have adverse effects on rapidly dividing cells, including germ cells in the testis.footnote-16 However, recently we observed that no differences were seen in testicular volume, FSH and testosterone levels, or sperm concentration, motility, and morphology in a population of fertile patients who smoke or drink coffee compared to patients that do not have these habits.footnote-17

Animal studies have shown that nicotine, cigarette smoke, and/or polycyclic aromatic hydrocarbons can cause testicular atrophy, poor sperm morphology, and overall impaired spermatogenesis, leading to the presence of oligospermia (<20 x 10⁶ sperm/mL or <40 x 10⁶ sperm) and teratospermia (<4% normal sperm forms). Serum levels of prolactin and estradiol (E₂) are also elevated in smokers. This was most pronounced in smokers who had low sperm counts compared to smokers who had normal sperm counts. Estradiol impairs spermatogenesis via several different mechanisms, including alteration of the HPG axis. Studies have also show that elevated E₂ levels can cause increased catecholamine levels, which in turn can produce ischemia of the seminiferous tubules. While the exact mechanism for the apparent elevation in E₂ in smokers is unknown, it appears to be due to increased production of this hormone rather than to decreased metabolic clearance.

It has been reported that cigarette smoking causes increased serum levels of norepinephrine, which in turn can increase aromatization of testosterone to E₂ in Sertoli cells in vitro.footnote-18 While it is unclear exactly how smoking directly affects spermatogenesis, overwhelming evidence suggests that it has an unfavorable impact on fertility. Thus, every effort should be made to counsel both partners to stop the use of tobacco as part of their infertility treatment.

Illicit drugs

Several illicit drugs are detrimental to male fertility and should be avoided, especially in men trying to establish a pregnancy.footnote-19 Marijuana interferes with spermatogenesis by decreasing sperm density and motility and decreasing the number with morphologic abnormalities.footnote-19 High doses of opiates lead to a decline in libido and erectile function. Opiates suppress the luteinizing hormone (LH) and
other agents such as angiotensin converting enzyme (ACE) inhibitors.

Due to its effect on the HPG axis, spironolactone may cause profound fertility problems. This agent also prevents the binding of dihydrotestosterone (DHT) to its receptor and inhibits the production of testosterone, which may result in reduced libido, erectile dysfunction, and significantly decreased sperm production.6,10,19

Calcium influx is critical for the normal acrosome reaction to occur.20 Thus, calcium channel blocking (CaCB) medications have recently received particular attention as potential inhibitors of the normal fertilization process. The calcium influx required during the acrosome reaction may be impaired directly by the effects of CaCBs or by insertion of the CaCBs into the plasma membrane of the sperm head. This insertion causes an alteration in the surface molecules expressed on the sperm head that are also required for normal fertilization to occur.20,21 Clinical studies have shown that cessation of the CaCB may reverse this process and restore the fertility in some otherwise infertile men. Other reports, however, have failed to show any adverse effect of CaCBs on male fertility.22 While the effects of CaCBs on male fertility remains unclear, it may be prudent to discuss a switch to another antihypertensive agent with patients who are taking these medications and who desire fertility.

Alpha-adrenergic blockers

Agents such as alfuzosin, tamsulosin, terazosin, and doxazosin are commonly prescribed for the treatment of benign prostatic hyperplasia, and are also used in younger men with voiding complaints. They function by blocking the motor sympathetic adrenergic nerve supply to the prostate, resulting in a reduction in urethral pressure.23 Differences in affinity for the α-receptor subtypes determine the side-effect profile for the individual agents.

The more selective alpha-blocking agents, by reducing smooth muscle tone at the bladder neck, can cause retrograde ejaculation.6 While patients tend to better tolerate and are more compliant with alfuzosin and tamsulosin than doxazosin, terazosin, and prazosin, retrograde ejaculation is more commonly associated with tamsulosin, occurring in about 8.5% of men. While ganglion blockers (methyldopa, guanethidine, and reserpine) can have similar side effects on male sexual function, they are rarely used clinically.6,23

Angiotensin converting enzyme inhibitors

Agents such as captopril and enalapril have not been associated with male sexual dysfunction or infertility, nor have direct vasodilators effects such as hydralazine and minoxidil.6

Psychotherapeutic agents

Psychotherapeutic agents exert much of their effect on male fertility by inhibiting sexual function and libido.

Antipsychotics

Most antipsychotics block dopamine in the CNS, leading to suppression of the HPG axis and decreased libido. Some antipsychotic agents also have alpha-adrenergic blocking effects that block innervation of the internal genital organs. In addition, some are vasodilators that can redirect blood away from the penis and cause erectile dysfunction. It is important to realize,
However, that antipsychotics can bring about important changes in overall well-being that may far outweigh any of the deleterious effects mentioned above.14,19

**Tricyclic antidepressants**

The use of tricyclic antidepressants or selective serotonin reuptake inhibitors (SSRIs) can lead to erectile dysfunction and reduced libido through their anticholinergic and sedative side effects.6,14,19 They have also been shown to impair ejaculation. Because these agents cause a delay in ejaculation, they have been used to treat men with premature ejaculation.

Perhaps the most significant side effect of antidepressants, however, is the potential for substantial elevation in serum prolactin concentrations. Hyperprolactinemia suppresses secretion of gonadotropin releasing hormone (GnRH) from the hypothalamus, and the high prolactin levels inhibit LH from binding to Leydig cells in the testes. These actions lead to significant but reversible suppression of spermatogenesis. If fertility is desired, the initial treatment of hyperprolactinemia caused by antidepressant use is a change to another class of medication. However, if this is not possible, cabergoline or bromocriptine can be administered.

**Other psychotherapeutic agents**

Phenothiazines can cause hyperprolactinemia and negatively affect male fertility in the same way as tricyclic antidepressants; thus, treatment is similar.6,10,14,19 Monoamine oxidase inhibitors, another prominent class of antidepressants, can cause erectile dysfunction or ejaculatory problems. Finally, lithium carbonate has been shown to decrease the action of dopamine in the CNS, causing decreased libido and potency.

**Chemotherapeutic agents**

The use of chemotherapeutic agents is necessary in the treatment of many malignancies that occur in young men, including Hodgkin’s lymphoma, testicular cancer, and acute lymphocytic leukemia.6,10,24,26 Chemotherapeutic agents have the potential to damage both germ cells and the supporting Sertoli cells, leading to severe oligospermia or azoospermia immediately following most courses of chemotherapy. While Leydig cells are less susceptible to injury than Sertoli cells, they may still demonstrate a degree of dysfunction, resulting in increased LH levels and low-normal testosterone levels. The most gonadotoxic chemotherapeutic agents include alkylating agents (cyclophosphamide, chlorambucil, and busulfan), antimetabolites (cytarabine), vinca alkaloids (vinblastine), and others (cisplatin, procarbazine, mechloretamine).27-29

While nearly all men will have profound defects in spermatogenesis immediately following chemotherapy, the ability to regain spermatogenesis following treatment varies depending on the individual agents used, the dose of each, and the length of treatment. Clearly, total destruction of the spermatogenic stem cells populating the testes leads to permanent sterility. However, it is often possible to limit damage to these chemosensitive cells by using combination therapies in which the individual dosages of the most toxic agents are reduced.24,29

During treatment with chemotherapeutic agents, attempts should be made to minimize damage to sperm-producing cells. One way to accomplish this is to use alternative chemotherapeutic agents such as methotrexate, which seems to be less harmful to testicular germ cells. Another way to decrease gonadotoxicity is to reduce the dose of alkylating agents and the number of cycles.27,28

It is not always possible to restore spermatogenesis following chemotherapy.24-26 It is therefore essential to offer patients the option of sperm cryopreservation prior to the initiation of chemotherapy. While some of these patients may have suboptimal semen quality prior to treatment, the use of in vitro fertilization technology coupled with intracytoplasmic sperm injection offers many men, even those with very low levels of sperm production, the potential to achieve a biologic pregnancy.24-26,29

Animal studies have shown that the use of certain hormonal treatments during the administration of cytotoxic chemotherapy may provide protective effects to germ cells. GnRH analogues and testosterone combine to suppress the concentration of intratesticular testosterone. When giving during cytotoxic chemotherapy, this type of treatment does not protect spermatogenesis from damage. Rather, it appears to accelerate the return of sperm production after treatment is completed. Hormonal treatment may “desensitize” supporting cells of the testis, making them less susceptible to harm from cytotoxic therapy, thereby enabling recovery of spermatogenesis. The primary supporting cell, but Leydig cells also appear to be involved. Further studies are necessary to demonstrate whether these protective effects will also be achieved in humans.30-32

**Hormones**

Several hormonal agents influence male fertility, including anabolic steroids, testosterone replacement therapies, and antiandrogens.

**Anabolic steroids**

Anabolic steroids are being used not only by body builders, but also by athletes in all age groups. Unfortunately, these agents may have devas-
tating effects on fertility. Anabolic steroids suppress the HPG axis via feedback inhibition.\(^6,10,14,19\) This causes severely reduced production of follicle-stimulating hormone (FSH) and LH resulting in hypogonadotropic hypogonadism.\(^14\) Steroid use may also cause erectile dysfunction by decreasing production of endogenous testosterone. High doses of anabolic steroids have also been shown to decrease sperm density and motility and increase morphologic abnormalities.

Fortunately, sperm production is likely to recover once steroid use is discontinued. While it generally takes 4 months for semen parameters to return to baseline levels, the continued presence of azoospermia has been reported 1 year after discontinuing anabolic steroid use.\(^6,10\) During this time, some men may benefit from injectable gonadotropins, such as human chorionic gonadotropin (hCG) replacement, to help stimulate sperm production and maintain endogenous testosterone production.

**Testosterone production**

With the increasing availability of safe, well-tolerated treatment methods, testosterone replacement therapy has become more common in clinical medicine. However, the use of exogenous androgens impairs spermatogenesis by inhibiting the HPG axis.\(^6,10,14,19\) Testosterone is also converted to estrogen in peripheral fat cells by the enzyme aromatase, increasing the negative feedback on the HPG axis. In men with decreased serum testosterone concentrations who wish to remain fertile, testosterone replacement in its various forms should not be used. An alternative in younger men with decreased serum testosterone concentrations is treatment with gonadotropins (such as hCG) or with the centrally-acting antiestrogen, clomiphene citrate. This agent has the advantage of being available in an oral form, while hCG requires repeated subcutaneous injection. However, both of these treatments will improve serum and intratesticular testosterone concentrations without decreasing gonadotropin levels through feedback inhibition.

**Other hormonal therapies**

Estrogens have been used in the past to treat advanced prostate cancer in men. Effects on sexual function include decreased libido, feminization, erectile dysfunction, and testicular atrophy. Finasteride is frequently used by men of reproductive age for its preventative effects on male-pattern baldness.\(^33\) While the use of this medication could conceivably alter intratesticular testosterone concentrations, there appears to be no evidence for any alteration in semen quality.

Saw palmetto is a commonly used herbal agent for symptoms of bladder outlet obstruction. While its mechanisms of action is largely unknown, it appears that it may exert some of its beneficial effect through slight estrogenic activity or by blocking the conversion of testosterone to DHT.\(^34\) While these effects could theoretically impair sperm production or function, no studies have yet been performed to evaluate this.

**Antibiotics**

Several commonly prescribed antibiotics may adversely affect fertility. Classically, high doses of nitrofurantoin have been shown to cause maturation arrest in the testis, most likely by preventing testicular cells from using carbohydrates and oxygen.\(^35\) However, low-dose, short-term therapy with nitrofurantoin has not been shown to have these same adverse effects. Erythromycin may reduce sperm motility and density.\(^35,36\) Due to the fact that tetracyclines bind to mature spermatozoa, they have the potential to affect sperm motility. While gentamicin and neomycin may directly inhibit spermatogenesis, in vitro studies have failed to show an effect on mature spermatozoa.

**Semen Quality**

Several reports in the literature have suggested a possible decline in human semen quality during the last 50 to 60 years.\(^37-40\) However, the decline in sperm counts has been suspected just to reflect changes in the policy of infertility treatment, or a bias in selection of patients, rather than a biological phenomenon.

A systematic analysis of 61 studies was undertaken by Carlsen in 1992. It showed a significant decrease in sperm concentration (from 113 million/mL to 66 million/mL) and semen volume (from 3.4 mL to 2.75 mL) over the period 1938-1990.\(^40\) These results have been discussed in the literature and have stimulated extensive research. In North America, the slope was somewhat less than previously reported. The decline in Europe was even greater than previously reported, whereas the few studies from other continents showed no trend.\(^37,38\) These results are consistent with those of Carlsen et al. and indicate that, after controlling for abstinence time, age, percent of men with proven fertility, and specimen collection method, there is a negative trend in sperm production in Europe and North America for the period 1934 to 1996. Over this period of time, the decrease is about 50%.

The larger single study undertaken in this subject comes from the analysis of 1351 healthy men volunteering for sperm donation in the sperm bank of Paris.\(^38\) After taking into account all potential covariates, there remained a yearly decrease of 2.6% in sperm concentration, 0.3% in percentage of motile
sperm, and 0.7% in the percentage of morphologically normal spermatozoa.

**Testicular dysgenesis syndrome**

Considerable concern has been raised in recent publications that estrogen-like compounds in either food or the environment cause adverse effects on reproductive health.\(^3\,\,^1\) There is clear evidence that reproductive disruption in wildlife may be caused by the environmental pollutants and more specifically by endocrine-disrupting compounds.\(^40\,\,\,^42\) Recently, cryptorchidism, hypospadias, testicular cancer, and poor semen quality have also been proposed to be the symptoms of one underlying cause, the testicular dysgenesis syndrome, which may develop during fetal life under the influence of environmental factors.\(^3\) However, there is only circumstantial evidence in humans that exposure to endocrine disruptors, especially diethylstilbestrol (DES), during pregnancy causes problems of reproductive health. The critical issue is whether there are enough high levels of endocrine disrupters in the ambient.

When these observations are brought together with the increasing incidence of testicular cancer in all the countries in which it is measured, and with the reported increased incidence of cryptorchidism and of hypospadias, the existence of a single syndrome, the “testicular dysgenesis syndrome” (TDS), that would associate these 3 elements, seems likely. These anomalies (decreasing sperm production, testicular cancer, and male genital tract malformations) are not necessarily associated in the same individuals, but they are statistically linked at the population level; however, one study showed that low sperm concentration, poor spermatozoa motility, and high proportion of morphologically abnormal spermatozoa were all associated with an increased risk in testicular cancer.\(^1\,\,^4\)

**Hypospadias**

There is some evidence for an increased hypospadias rate during the last few decades.\(^43\,\,^44\) Several explanations have been proposed, including increased exposure to endocrine disruptors during fetal life. Another possible explanation is that, since published hypospadias rates are exclusively derived from birth-defect registries, artefacts in these registries may account for the reported changes over time. Recently, Dolk et al., discussed the possibility that the rise in hypospadias is caused by an increasing tendency to report minor hypospadias.\(^45\) However, the hypothesis is difficult to prove, since very few studies report the total distribution of cases by severity.

**Cryptorchidism**

There are also indications that cryptorchidism may have increased in incidence in several countries, but in general, cryptorchidism is registered more unreliably than hypospadias.\(^46\) Also, this anomaly is regarded as being associated with exposure to endocrine disruptors in utero.

Transinguinal descent of the testes also depends on androgens, but disrupted androgen action can only explain a very small proportion of cases with cryptorchidism.\(^47\) Neonatal exposure to DES in male rats caused major developmental abnormalities of the testis, epididymis, vas deferens, seminal vesicles, and prostate when evaluated at the time of normal onset of puberty.\(^48\)

**Testicular cancer**

The most convincing evidence for a gene decline in male reproductive health in humans is the increase in testicular cancer noted in the recent past in several Western countries.\(^4\,\,^{27-29}\) Both cryptorchidism and hypospadias are associated with an increased risk of testicular cancer, based on the observation that men with cryptorchidism/hypospadias are over-represented among patients with testicular cancer.\(^1\)

The hypothesis that endocrine disruption can cause cancer in humans is based on the association between DES exposure of pregnant women and clear cell adenocarcinoma of the vagina and cervix in their female offspring. Some of the male offspring of women who took DES show pseudohermaphroditism and genital malformations, including epididymal cysts, small testes, microphallus, and reduced semen quality.\(^49\) Follow-up surveys of DES-exposed male offspring have shown no impairment in fertility or sexual function, or evidence of an increased risk of testicular cancer. Dysgenic testes have a very high risk of developing testicular cancer in adulthood; these cancers seem to arise from premalignant gonocytes or in situ carcinoma cells.\(^1\,\,^{29}\)

RESUMO


A infertilidade afeta até 15% da população sexualmente ativa e em 50% dos casos, o fator masculino está envolvido, como problema primário ou em combinação com causas de origem feminina. Como muitas drogas comumente encontradas e medicações
podem ter efeitos deletérios na fertilidade masculina, a avaliação médica deve incluir uma discussão sobre o uso de drogas recreacionais e ilícitas, medicamentos e outras substâncias podem prejudicar a fertilidade. Com o conhecimento de quais drogas e medicamentos podem ser prejudiciais à fertilidade talvez seja possível mudar os hábitos ou a posologia das medi-
cações para diminuir os efeitos adversos na fertilidade e aumentar as chances de engravidar com sucesso.

Preocupações referentes ao desenvolvimento sexual masculino e reprodução têm mudado para a pior nos últimos 30-50 anos. Embora alguns relatos não demonstrem modificações, outros sugerem que a concentração espermática esteja diminuindo e que a incidência de anormalidades do desenvolvimento como hipospádia e criptorquidia parecem estar aumentan-
do, assim como a incidência de câncer de testículo. Estas preocupações sobre a possibilidade do ambiente estar contami-


REFERENCES


